Lumos Pharma Inc. (LUMO) is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of therapeutics for rare diseases. The company's lead drug candidate, LUM-201, is a small molecule designed to stimulate growth hormone release and is being developed for the treatment of Pediatric Growth Hormone Deficiency (PGHD) and other rare endocrine disorders. Lumos Pharma is also developing a pipeline of other product candidates for rare diseases, including LUM-204 for the treatment of Creatine Transporter Deficiency (CTD) and LUM-301 for the treatment of Idiopathic Hypersomnia (IH).
Lumos Pharma was founded in 2011 and is headquartered in Austin, Texas. The company is focused on leveraging its expertise in rare diseases to develop and commercialize innovative therapies that address unmet medical needs.
Lumos Pharma Inc. (LUMO) is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of therapeutics for rare diseases. The company's lead drug candidate, LUM-201, is a small molecule designed to stimulate growth hormone release and is being developed for the treatment of Pediatric Growth Hormone Deficiency (PGHD) and other rare endocrine disorders. Lumos Pharma is also developing a pipeline of other product candidates for rare diseases, including LUM-204 for the treatment of Creatine Transporter Deficiency (CTD) and LUM-301 for the treatment of Idiopathic Hypersomnia (IH).